{"classes":[{"categories":[{"measurements":[{"comment":"Median and Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG000","lowerLimit":"34.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of first dose until death due to any causes. Subjects not known to have died at the time of analysis are censored at the last recorded date on which the subject was known to be alive. Median overall survival calculated using the Kaplan-Meier method.\n\nPer the protocol, the safety run-in treatment arms were combined and analyzed regardless of chemotherapy received for consistency with the randomized component.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes all participants in both Safety Run-In treatment arms: AZD9291 + Carboplatin + Pemetrexed and AZD9291 + Cisplatin + Pemetrexed","id":"OG000","title":"Overall Safety Run-In Participants"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Set, includes all participants in the Safety Run-In Treatment Arms who received at least 1 dose of study treatment (osimertinib, cisplatin, carboplatin, or pemetrexed).","reportingStatus":"POSTED","timeFrame":"Up to 45 months (maximum follow up 44.6 months)","title":"Overall Survival (OS) (Safety Run-In Treatment Arms Only)","type":"SECONDARY","unitOfMeasure":"Months"}